ArticleOncotarget2016
Loss of ZG16 is regulated by miR-196a and contributes to stemness and progression of colorectal cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Up-regulation of SLC26A3 enhances oxaliplatin sensitivity in colorectal cancer.Discover oncology · 2026Article
- Transcriptomic Profiling Reveals Isoform-Specific Regulatory Roles of miR-196A and miR-196B in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization.Frontiers in immunology · 2025Article
- Integrative subtyping by bile acid metabolism identifiesFrontiers in oncology · 2025Article
- ZG16 enhances the maturation of dendritic cells via induction of CD40 and contributes to the antitumor immunity in pancreatic cancer.Oncogene · 2024Article
- Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer.Scientific reports · 2024Article
- Identification and validation of metastasis-related gene ZG16 in the prognosis and progression in colorectal cancer.Frontiers in oncology · 2024Article
- An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer.BMC cancer · 2022Article
- Knockdown of miR-92a suppresses the stemness of colorectal cancer cells via mediating SOCS3.Bioengineered · 2022Article
- Genome-Wide Analysis of microRNA and mRNA Expression in Colorectal Intramucosal Neoplasia and Colorectal Cancer With a Microsatellite-Stable Phenotype Based on Adenoma-Carcinoma Sequences.Frontiers in oncology · 2022Article
- Conformational switches and redox properties of the colon cancer-associated human lectin ZG16.The FEBS journal · 2021Article
- ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.BMC cancer · 2021Article
- The Construction and Comprehensive Analysis of Inflammation-Related ceRNA Networks and Tissue-Infiltrating Immune Cells in Ulcerative Progression.BioMed research international · 2021Article
- Article
- MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer.Molecular biology reports · 2020Review
- Identification of hub genes in colon cancer via bioinformatics analysis.The Journal of international medical research · 2020Article
- Article
- A Novel Prognostic Score Based onPharmacogenomics and personalized medicine · 2020Article
- Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.Epigenetics · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most common malignant tumour and the leading cause of cancer-related mortality worldwide. Clarification of the mechanism that underlies CRC tumorigenesis and progression therefore is urgently needed ffor developing novel therapies. Through analysis of The Cancer Genome Atlas (TCGA) dataset, we identified an interesting gene, ZG16, which is significantly decreased in CRC samples compared to adjacent non-tumor tissues and associated with prognosis of patients. We found that the expression of ZG16 correlated with CRC related genes which were regulated by APC/CTNNB1 pathway. Interestingly, the expression of ZG16 was negatively correlated with CRC stem cell marker, LGR5. Overexpression of ZG16 significantly inhibits growth and sphere formation of stem-like CRC cells. Moreover, we also identified an upstream regulator of ZG16, miR-196a, which was significantly overexpressed in CRC and promotes cell growth and stemness. In conclusion, this study demonstrated that loss of ZG16 is regulated by miR-196a and contributes to stemness and progression of CRC, which may provide a promising therapeutic strategy for advanced CRCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.